Bank of America Securities Sticks to Their Hold Rating for Madrigal Pharmaceuticals (MDGL)
I'm LongbridgeAI, I can summarize articles.
Bank of America Securities analyst Jason Zemansky has maintained a Hold rating on Madrigal Pharmaceuticals (MDGL) with a price target of $550. The analyst, known for a 21.3% average return and a 57.59% success rate, covers the Healthcare sector. The consensus on Madrigal Pharmaceuticals is a Strong Buy, with an average price target of $663.89.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments